Eye Health America

eyehealthamerica.com

Eye Health America partners with eye care practices and ambulatory surgery centers to provide superior clinical care. Our member practices offer full-service eye care from routine eye exams, contact lenses and glasses to medical ophthalmology and surgery including cataract, cornea, retina, glaucoma, pediatrics and oculoplastics. We support practice groups and ASCs as they grow locations and service offerings, enabling them to focus on delivering the highest quality outcomes and meeting a rapidly growing need for eye care. Visit www.eyehealthamerica.com to learn more.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

GENOMIC VISION ENTERS DISTRIBUTION AGREEMENT WITH CLINISCIENCES

biotechnology news | June 23, 2023

news image

Genomic Vision a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce an exclusive European distribution agreement with CliniSciences. CliniSciences is a major European distributor of innovative products and services in Life Science Research with a particular focus on oncology. CliniSciences and Genomic Vision will work closely together to leverage their respective resources, i...

Read More

Industrial Impact

GILEAD AND MACROGENICS ANNOUNCE ONCOLOGY COLLABORATION TO DEVELOP BISPECIFIC ANTIBODIES

Gilead and MacroGenics | October 18, 2022

news image

Gilead Sciences, Inc. and MacroGenics announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia and myelodysplastic syndromes. A leader in the bispecific...

Read More

Diagnostics

ONCODE INSTITUTE AND ARGOBIO LAUNCH LAIGO BIO, A TARGETED PROTEIN DEGRADATION BIOTECH WITH PROGRAMS IN ONCOLOGY AND NEUROLOGICAL DISORDERS

ArgoBio and Oncode Institute | February 08, 2022

news image

ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR. The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of ...

Read More

Industrial Impact, Medical

SOPHIA AND MSKCC PARTNER TO COMBINE CANCER ANALYSIS TECHNOLOGY FOR LIQUID BIOPSIES

SOPHiA GENETICS | January 13, 2023

news image

SOPHiA GENETICSTM, a leading cloud-native software firm in the healthcare industry, recently announced that it has partnered with Memorial Sloan Kettering Cancer Center (MSKCC) to provide physicians and researchers with new testing and analytic capabilities. The collaboration includes the incorporation of proprietary Comprehensive Genomic Panel (CGP) sequencing tests, such as MSK-ACCESS®, which SOPHiA GENETICS will market as the first comprehensive ctDNA liquid biopsy test p...

Read More
news image

Medical

GENOMIC VISION ENTERS DISTRIBUTION AGREEMENT WITH CLINISCIENCES

biotechnology news | June 23, 2023

Genomic Vision a Euronext-listed biotechnology company that develops products and services for the highly accurate characterization of DNA sequences, is pleased to announce an exclusive European distribution agreement with CliniSciences. CliniSciences is a major European distributor of innovative products and services in Life Science Research with a particular focus on oncology. CliniSciences and Genomic Vision will work closely together to leverage their respective resources, i...

Read More
news image

Industrial Impact

GILEAD AND MACROGENICS ANNOUNCE ONCOLOGY COLLABORATION TO DEVELOP BISPECIFIC ANTIBODIES

Gilead and MacroGenics | October 18, 2022

Gilead Sciences, Inc. and MacroGenics announced an exclusive option and collaboration agreement to develop MGD024, an investigational, bispecific antibody that binds CD123 and CD3 using MacroGenics’ DART® platform, and two additional bispecific research programs. The collaboration agreement grants Gilead the option to license MGD024, a potential treatment for certain blood cancers, including acute myeloid leukemia and myelodysplastic syndromes. A leader in the bispecific...

Read More
news image

Diagnostics

ONCODE INSTITUTE AND ARGOBIO LAUNCH LAIGO BIO, A TARGETED PROTEIN DEGRADATION BIOTECH WITH PROGRAMS IN ONCOLOGY AND NEUROLOGICAL DISORDERS

ArgoBio and Oncode Institute | February 08, 2022

ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR. The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of ...

Read More
news image

Industrial Impact, Medical

SOPHIA AND MSKCC PARTNER TO COMBINE CANCER ANALYSIS TECHNOLOGY FOR LIQUID BIOPSIES

SOPHiA GENETICS | January 13, 2023

SOPHiA GENETICSTM, a leading cloud-native software firm in the healthcare industry, recently announced that it has partnered with Memorial Sloan Kettering Cancer Center (MSKCC) to provide physicians and researchers with new testing and analytic capabilities. The collaboration includes the incorporation of proprietary Comprehensive Genomic Panel (CGP) sequencing tests, such as MSK-ACCESS®, which SOPHiA GENETICS will market as the first comprehensive ctDNA liquid biopsy test p...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us